Johnson & Johnson (ETR:JNJ)
Germany
· Delayed Price · Currency is EUR 136.54
-1.26 (-0.91%)
Apr 23, 2025, 5:35 PM CET
Johnson & Johnson Revenue
Johnson & Johnson had revenue of $21.89B USD in the quarter ending March 30, 2025, with 2.39% growth. This brings the company's revenue in the last twelve months to $89.33B, up 4.30% year-over-year. In the year 2024, Johnson & Johnson had annual revenue of $88.82B with 4.30% growth.
Revenue (ttm)
$89.33B
Revenue Growth
+4.30%
P/S Ratio
3.99
Revenue / Employee
$646.86K
Employees
138,100
Market Cap
329.40B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 29, 2024 | 88.82B | 3.66B | 4.30% |
| Dec 31, 2023 | 85.16B | 5.17B | 6.46% |
| Jan 1, 2023 | 79.99B | 1.25B | 1.59% |
| Jan 2, 2022 | 78.74B | -3.84B | -4.65% |
| Jan 3, 2021 | 82.58B | 525.00M | 0.64% |
| Dec 29, 2019 | Pro | Pro | Pro |
| Dec 30, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Jan 1, 2017 | Pro | Pro | Pro |
| Jan 3, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Merck KGaA | 21.16B |
| Siemens Healthineers AG | 22.67B |
| Fresenius SE & Co. KGaA | 21.83B |
| Bayer Aktiengesellschaft | 46.61B |
| Sartorius Aktiengesellschaft | 3.44B |
| Fresenius Medical Care AG | 19.34B |
| Carl Zeiss Meditec AG | 2.08B |
| Fielmann Group AG | 2.16B |
Johnson & Johnson News
- 15 hours ago - Dividend Kings Down Today: Why Johnson & Johnson (JNJ), Coca-Cola (KO) and Procter & Gamble (PG) Are Sliding - 24/7 Wall street
- 16 hours ago - 2025 Dividend Kings: Weathering Tariff Volatility Better Than The Market - Seeking Alpha
- 1 day ago - Two Stocks To Consider During Market Unrest To Provide Income Stability - Seeking Alpha
- 2 days ago - JNJ says new data buoys TAR-200 monotherapy for bladder cancer - Seeking Alpha
- 2 days ago - Rep. Thomas Kean Has Bought Up to $45K Worth Of Illumina Stock: Here's What You Should Know - Benzinga
- 2 days ago - Johnson & Johnson unveils highly anticipated and potential practice-changing data in bladder cancer treatment at AUA - PRNewsWire
- 2 days ago - LLY, NVO and AMGN Forecast – Pharma Stocks to Open Mixed - FXEmpire
- 3 days ago - IBM, Parker-Hannifin Among 10 Companies To Announce Dividend Increases In Second Half Of April - Seeking Alpha